NCT06341855View on ClinicalTrials.gov

Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions
Endometrial Cancer
Interventions
DIAGNOSTIC_TEST

MRD-ctDNA

ctDNA-MRD is a powerful biomarker, and ctDNA-MRD is a reliable predictive biomarker in EC.

Trial Locations (1)

Unknown

RECRUITING

the 1st hospital of Jilin University, Changchun

All Listed Sponsors
collaborator

Geneplus-Beijing Co. Ltd.

INDUSTRY

lead

The First Hospital of Jilin University

OTHER